Incidence and risk factors associated with progression to severe pneumonia among adults with non–severe Legionella pneumonia

Jin-Young Huh1,2, Sang-Ho Choi3, Kyung-Wook Jo2, Jin Won Huh1, Sang-Bum Hong1, Tae Sun Shim1, Chae-Man Lim1, Younsuck Koh1

1Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 2Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong; 3Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background: Legionella species are important causative organisms of severe pneumonia. However, data are limited on predictors of progression to severe Legionella pneumonia (LP). Therefore, the risk factors for LP progression from non–severe to the severe form were investigated in the present study.

Methods: This was a retrospective cohort study that included adult LP patients admitted to a 2,700-bed referral center between January 2005 and December 2019.

Results: A total of 155 patients were identified during the study period; 58 patients (37.4%) initially presented with severe pneumonia and 97 (62.6%) patients with non–severe pneumonia. Among the 97 patients, 28 (28.9%) developed severe pneumonia during hospitalization and 69 patients (71.1%) recovered without progression to severe pneumonia. Multivariate logistic regression analysis showed platelet count ≤150,000/mm3 (odds ratio [OR], 2.923; 95% confidence interval [CI], 1.100–8.105; P=0.034) and delayed antibiotic treatment >1 day (OR, 3.092; 95% CI, 1.167–8.727; P=0.026) were significant independent factors associated with progression to severe pneumonia.

Conclusions: A low platelet count and delayed antibiotic treatment were significantly associated with the progression of non–severe LP to severe LP.

Key Words: antibiotics; Legionella; pneumonia; prognosis; thrombocytopenia

INTRODUCTION

Legionella species (spp.) are small Gram-negative bacilli usually found in natural aqueous environments [1,2]. The bacteria can cause respiratory infection in humans and are an important causative organism of pneumonia [3,4]. Legionella pneumonia (LP) accounts for 2.4%–12.5% of community-acquired pneumonia (CAP) cases [5,6]. In the last decade, the incidence of LP has rapidly increased worldwide [7-9]. The number of cases reported to the Korea Centers for Disease Control and Prevention was 6 in 2006 in contrast to 501 in 2019
The reasons for such a sharp increase include widespread nucleic acid amplification, urinary antigen testing, and the introduction of mandatory reporting systems for the disease in several countries [11-13]. Furthermore, an aging population, infrastructure, and changes in the global climate have been suggested as factors contributing to this increase [14].

In prior studies, 20.7%–78.6% of LP patients were shown to initially have or eventually progress to severe pneumonia requiring intensive care unit (ICU) admission [15-18]. Despite the growing importance of LP in public health, the issues associated with the progression of LP have been addressed in only a few studies. Therefore, in the present study, the risk factors associated with the progression of non-severe LP to severe LP in adults were investigated.

**MATERIALS AND METHODS**

The study protocol was approved by the Institutional Review Board of Asan Medical Center (No. 2021-2424). The requirement for informed consent was waived due to the retrospective nature of the analysis.

**Study Population and Data Collection**

Patients whose clinical specimens yielded positive results for *Legionella* spp. between January 2005 and December 2019 at Asan Medical Center, a 2,700-bed tertiary hospital, were screened for this study. Using the clinical microbiology electronic database of the hospital, 170 LP patients >18 years of age were identified, their medical records were reviewed, and patients treated in-hospital for LP were selected. Finally, a total of 155 patients were included in the present study (Figure 1). Data on demographics, underlying diseases or conditions, clinical manifestations, laboratory and radiologic findings, pathogens, treatment, and outcomes were retrospectively collected from the electronic records. Survival data were obtained from the National Health Insurance records.

**Definitions**

A LP case was defined as a patient with pneumonia whose specimens yielded microbiologic evidence of *Legionella* spp. The diagnosis of pneumonia was confirmed if the patient presented with new or increased cough, sputum, fever or hypothermia, abnormal white blood cell count, or elevated C-reac-

---

**KEY MESSAGES**

- Among 155 patients with *Legionella* pneumonia at presentation, 58 patients (37.4%) had severe pneumonia and 97 patients (62.6%) had non-severe pneumonia; 28 of the 97 patients (28.9%) progressed to severe pneumonia.
- Platelet count ≤150,000/mm$^3$ and delayed antibiotic treatment >1 day were factors associated with progression to severe pneumonia in initially non-severe *Legionella* pneumonia patients.

---

**Figure 1.** Flowchart of study findings.
Severe Legionella pneumonia was defined as septic shock due to the need for vasopressor administration, respiratory failure requiring mechanical ventilation, as defined in the American Thoracic Society and Infectious Disease Society of America’s guidelines [19], or PaO₂/FiO₂ (partial pressure of arterial oxygen/fraction of inspired oxygen) ratio <200. The criteria for clinical stability were temperature ≤37.8°C, heart rate ≤100 beats/min, respiratory rate ≤24 breaths/min, systolic blood pressure ≥90 mm Hg, arterial oxygen saturation ≥90% or pO₂ ≥60 mm Hg on room air, ability to maintain oral intake, and normal mental status [20].

Adequate antibiotic treatment was defined as the use of macrolides or fluoroquinolones. Although other classes of empirical antibiotics were also frequently administered, they were not categorized as “adequate” due to their lack of efficacy against LP. The macrolides used in this study were clarithromycin and azithromycin. The fluoroquinolones included ciprofloxacin, levofloxacin, and moxifloxacin. Chronic lung diseases included chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, emphysema, asthma, and chronic bronchitis.

Statistical Analysis
Continuous variables were compared using Student t-test or Mann-Whitney test as appropriate. Categorical variables were compared using chi-square test or Fisher’s exact test. The relationship among risk factors for progression to severe pneumonia was evaluated using logistic regression analysis. Factors with P<0.1 in univariate analysis were selected for multivariate analysis. Statistical analysis was performed using R version 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria). All tests of significance were two-sided, and P<0.05 was considered statistically significant (two-tailed).

RESULTS
Baseline Characteristics
The baseline characteristics of the 155 included patients are presented in Table 1. The mean number of patients per year increased from 5.2 per year between 2005 and 2009 to 12.9 per year between 2010 and 2019. The mean age was 64.9 years and 76.1% of patients were male. CAP was the most common (45.2%) and 34.8% and 20.0% of patients had healthcare-associated pneumonia and hospital-acquired pneumonia, respectively. A total of 89 patients (57.4%) were immunocompromised. The most common symptom was fever (67.1%), followed by sputum (63.9%) and cough (62.6%). A total of 22 patients (14.2%) had altered mental status. At LP diagnosis, the median serum sodium concentration was 134.0 mmol/L and the median C-reactive protein level was 16.8 mg/dl. The median leukocyte and platelet counts were 9,200/mm³ and 174,000/mm³, respectively. A total of 65 patients had thrombocytopenia (<150,000/mm³). Radiologic examination revealed bilateral lung involvement in 58.7% of patients and pleural effusion in 16.1% of patients.

Treatment and Clinical Outcomes of LP
During hospitalization, most patients (98.7%) were treated with macrolides, fluoroquinolones, or both for LP. Fluoroquinolone therapy, without macrolide was administered to 102 patients (65.8%) and macrolide therapy without fluoroquinolone was administered to 11 patients (7.1%). A combination of both was administered to 40 patients (25.8%). At presentation, 58 patients (37.4%) had severe pneumonia. Among the 97 patients without severe pneumonia (62.6%, 97/155), 28 patients (28.9%, 28/97) progressed to severe pneumonia and 69 patients (71.1%, 69/97) recovered without deterioration (Figure 1). At presentation, leukocyte and platelet counts were lower in the progressed group than in the non-progressed group; however, other baseline characteristics were comparable (Table 2). Clinical stability was achieved in 60 patients and the median time since the presentation of LP was 6 days (interquartile range, 4–11 days). The 90-day mortality rates of patients with non-severe LP, initially severe LP, and severe LP after progression were 17.4% (12/69), 53.4% (31/58), and 75.0% (21/28), respectively (P=0.001).

Risk Factors for Progression to Severe Pneumonia in LP
Table 3 shows analysis of the risk factors for progression to severe pneumonia in LP.
Table 1. Baseline characteristics of 155 Legionella pneumonia patients included in the study

| Characteristics                  | Value          |
|----------------------------------|----------------|
| Number of patients               | 155            |
| Age (yr)                         | 64.9±12.9      |
| Male                             | 116 (76.1)     |
| Body mass index (kg/m²)          | 22.2±3.4       |
| Current smoker                   | 19 (12.3)      |
| Category of pneumonia            |                |
| Community-acquired pneumonia     | 70 (45.2)      |
| Healthcare-associated pneumonia  | 54 (34.8)      |
| Hospital-acquired pneumonia      | 31 (20.0)      |
| Comorbidity                      |                |
| Immunocompromised statea)        | 89 (57.4)      |
| Diabetes mellitus                | 39 (25.2)      |
| Chronic lung disease             | 30 (19.4)      |
| Chronic obstructive pulmonary disease | 12 (40.0) |
| Interstitial lung disease        | 8 (26.7)       |
| Bronchiectasis                   | 5 (16.7)       |
| Emphysema                        | 3 (10.0)       |
| Chronic bronchitis               | 1 (3.3)        |
| Asthma                            | 1 (3.3)        |
| Chronic kidney disease           | 26 (16.8)      |
| Chronic heart disease            | 18 (11.6)      |
| Liver cirrhosis                  | 13 (8.4)       |
| Clinical finding                 |                |
| Fever                            | 104 (67.1)     |
| Sputum                           | 99 (63.9)      |
| Cough                            | 97 (62.6)      |
| Dyspnea                          | 80 (51.6)      |
| Altered mental status           | 22 (14.2)      |
| Chest discomfort                 | 17 (11.0)      |
| Diarrhea                         | 17 (11.0)      |
| Headache                         | 5 (6.9)        |
| Laboratory finding               |                |
| Leukocytes (×10³/mm³)            | 9,200 (4,100–13,500) |
| Platelets (×10³/mm³)             | 174.0 (91.5–238.5) |
| Blood urea nitrogen (mg/dl)      | 24.0 (17.5–37.5) |
| Sodium (mMol/L)                  | 134.0 (130.0–137.0) |
| Lactate dehydrogenase (U/L)      | 362.0 (255.0–481.0) |
| C-reactive protein (mg/dl)       | 16.8 (8.3–27.2) |
| PaO₂/FiO₂ ratio                  | 276.2 (206.7–342.8) |
| Radiologic finding               |                |
| Multilobar involvement           | 104 (67.1)     |
| Bilateral involvement            | 91 (58.7)      |
| Pleural effusion                 | 25 (16.1)      |
| Pneumonia severity               |                |
| CURB-65 score                    | 2 (1–2)        |

Values are presented as mean±standard deviation, number (%), or median (interquartile range).
PaO₂: partial pressure of arterial oxygen; FiO₂: fraction of inspired oxygen; CURB-65: confusion, uremia, blood pressure, age ≥65 years.

a) An immunocompromised state was defined if one of the following criteria were met: (1) receiving immunosuppressants daily, including corticosteroids; (2) infection with human immunodeficiency virus; (3) receiving solid organ or hematopoietic stem cell transplantation; (4) receiving chemotherapy for underlying malignancy during the previous 6 months; and (5) presence of other underlying immunodeficiency disorders.

severe pneumonia for the 97 patients with initially non-severe LA. In univariate analysis, platelet count ≤150,000/mm³ (odds ratio [OR], 3.30; 95% confidence interval [CI], 1.34–8.43; P=0.010) and delayed antibiotic treatment >1 day (OR, 2.75; 95% CI, 1.11–7.10; P=0.032) were significant factors associated with the development of severe pneumonia during hospitalization. In addition, immunocompromised state (OR, 2.35; 95% CI, 0.93–6.38; P=0.078) and bilateral involvement on radiologic examination (OR, 2.13; 95% CI, 0.88–5.35; P=0.098) were included for multivariate analysis. Multivariate analysis identified platelet count ≤150,000/mm³ (adjusted OR [aOR], 2.92; 95% CI, 1.10–8.11; P=0.034) and delayed antibiotic treatment >1 day (aOR, 3.09; 95% CI, 1.17–8.73; P=0.026) as independent risk factors for severe disease in LP.

DISCUSSION

In the present study, approximately one-third of patients initially had severe LP at the time of hospital presentation. Among the remaining two-thirds of patients with non-severe LP, one-quarter progressed to severe pneumonia during hospitalization. Risk factors associated with the development of severe pneumonia were low platelet count and delayed antibiotic treatment. Overall, the death rate was high among patients who progressed to severe LP.

The high percentage of severe pneumonia among patients with LP in this study is comparable to the findings in several previous studies. In a prospective study conducted in Spain, among 30 hospitalized LP patients, 50% had respiratory failure [15]. The outcomes of 14 LP patients were reported in a Canadian study and 78.6% (11/14) required ICU admission [16]. However, conflicting results have also been reported. In a large prospective French study, 27.4% (30/540) of 540 community-acquired LP patients required ICU care [17]. In a study in Italy, 20.7% (24/116) of 116 patients retrospectively analyzed required ICU admission [18]. These discrepancies may be attributed to differences in the patient population and number of participants. The present study was relatively large and performed at a tertiary care hospital. The inclusion of immunocompromised patients may have contributed to the relatively high rate of severe LP.

A low platelet count has been associated with the progression of non-severe LP. In a recent prospective cohort study involving 250 hospitalized CAP patients, both ICU admission rate and the rate of mechanical ventilation were higher in the thrombocytopenia group (<100,000/mm³) [21]. In another
Huh JY, et al. **Severe Legionella pneumonia**

Table 2. Baseline characteristics of Legionella pneumonia patients who progressed or did not progress to severe pneumonia

| Characteristics                  | Progressed     | Non-progressed | P-value |
|----------------------------------|----------------|----------------|---------|
| Number of patients               | 28             | 69             | -       |
| Age (yr)                         | 66.0±11.2      | 63.0±14.2      | 0.327   |
| Male                             | 24 (85.7)      | 49 (71.0)      | 0.207   |
| Body mass index (kg/m²)          | 23.5±3.4       | 22.2±3.4       | 0.098   |
| Current smoker                   | 2 (7.1)        | 10 (14.5)      | 0.312   |
| Immunocompromised statea)        | 20 (71.4)      | 34 (51.5)      | 0.119   |
| Chronic lung disease             | 5 (17.9)       | 15 (21.7)      | 0.880   |
| Leukocytes (L/mm³)               | 7,850 (3,150–10,775) | 9,800 (6,500–15,100) | 0.040 |
| Platelets (x10³/mm³)             | 102 (44.5–180.5) | 193 (131–269) | <0.001 |
| Protein (mg/dl)                  | 5.9±0.9        | 6.3±1.0        | 0.361   |
| Albumin (mg/dl)                  | 2.5±0.6        | 2.8±0.6        | 0.203   |
| Sodium (mmol/L)                  | 134.5 (131.8–136.2) | 134.0 (130.0–137.0) | 0.984 |
| Blood urea nitrogen (mg/dl)      | 20.5 (18.0–29.0) | 22 (22.0–34.0) | 0.837   |
| PaO₂/FiO₂ ratio ≤300             | 12 (42.9)      | 18 (26.1)      | 0.169   |
| Bilateral involvement            | 17 (60.7)      | 29 (42.0)      | 0.148   |
| Pleural effusion                 | 2 (7.1)        | 10 (14.5)      | 0.512   |
| Fluoroquinolone use              | 24 (85.7)      | 60 (87.0)      | >0.999  |
| Macrolide use                    | 10 (35.7)      | 24 (34.8)      | >0.999  |
| Both fluoroquinolone and macrolide use | 15 (21.7)    | 8 (28.6)      | 0.650   |
| CURB-65 score                    | 2 (1–2)        | 1 (1–2)        | 0.236   |

Values are presented as mean±standard deviation, number (%), or median (interquartile range). PaO₂: partial pressure of arterial oxygen; FiO₂: fraction of inspired oxygen; CURB-65: confusion, uremia, blood pressure, age ≥65 years.

a) An immunocompromised state was defined if one of the following criteria were met: (1) receiving immunosuppressants daily, including corticosteroids; (2) infection with human immunodeficiency virus; (3) receiving solid organ or hematopoietic stem cell transplantation; (4) receiving chemotherapy for underlying malignancy during the previous 6 months; and (5) presence of other underlying immunodeficiency disorders.

Table 3. Risk factors for progression to severe pneumonia among 97 patients who were initially presented with non-severe Legionella pneumonia

| Risk factor                                    | Univariate analysis | Multivariate analysis |
|------------------------------------------------|---------------------|----------------------|
|                                                | OR                  | 95% CI                | P-value |
| CURB-65 score                                  | 1.311               | 0.782–2.313           | 0.308   |
| Body mass index                                | 1.121               | 0.982–1.296           | 0.101   |
| Chronic lung disease                           | 0.945               | 0.806–1.110           | 0.329   |
| Leukocytes <4,000/mm³                          | 0.600               | 0.233–2.293           | 0.669   |
| Platelets ≤150,000/mm³                         | 0.783               | 0.934–6.377           | 0.078   |
| PaO₂/FiO₂ ratio ≤300                           | 0.783               | 0.934–6.377           | 2.104   |
| Bilateral involvement on CXR                   | 0.694               | 0.326–1.484           | 0.329   |
| Delayed antibiotic treatment >1 day            | 1.219               | 1.051–1.403           | 0.032   |
| Fluoroquinolone use                            | 0.900               | 0.526–1.534           | 0.871   |
| Macroline use                                  | 1.042               | 0.406–2.583           | 0.931   |
| Both fluoroquinolone and macroline use         | 1.440               | 0.512–3.864           | 0.475   |

OR: odds ratio; CI: confidence interval; CURB-65: confusion, uremia, blood pressure, age ≥65 years; PaO₂: partial pressure of oxygen; FiO₂: fraction of inspired oxygen; CXR: chest X-ray.

A retrospective cohort study involving 500 hospitalized patients with CAP, thrombocytopenia was significantly associated with death [22]. The present study results are in agreement with these studies, indicating a low platelet count might be
predictive of non-severe LP progressing to severe LP. Platelets play various roles in the immune response; they can recognize pathogenic bacteria or toxins, induce the acute phase response, and promote the innate immune cell response [23]. Recently, streptococcal M1 protein was shown to activate platelets, resulting in the acquisition of C1q on the surface of the platelets and increase apoptosis and phagocytosis [24]. A similar mechanism for enhancing complement activity may be present in Legionella spp. The L. pneumophila lipopolysaccharide activates the classical complement pathway [25]. In a study of samples from infected patients, an activation of platelets and thrombocytopenia was observed [26]. In addition, L. pneumophila is an intracellular organism that utilizes complement receptors for entry into monocytes for replication [27]. A decreased platelet count may indirectly indicate susceptibility to Legionella infection.

In the present study, delayed antibiotic treatment >1 day was a risk factor for progression to severe pneumonia, which is consistent with a recent Italian study [10]. The investigators showed macrolide/levofloxacin administration within 24 hours of admission was associated with fewer transfers to the ICU (OR, 0.20; 95% CI, 0.05–0.73). In a Taiwanese study, the ICU admission rate was also reportedly higher in patients who received delayed treatment compared with subjects who received timely antibiotic treatment (68.7% vs. 31.2%) [28]. The importance of administering antibiotics in a timely manner has also been demonstrated for all-cause pneumonia [29]. Our finding reemphasizes the importance of adequate early therapy for non-severe LP as well as severe LP.

The present study had several limitations. First, this was a retrospective study performed at a single referral center. Approximately half the patients were immunocompromised. Due to the possibility of selection bias of the study population, the results may not be generalizable to other patient populations. Second, patients who were not hospitalized were excluded from the analysis which may have been a source of bias. However, the number of excluded patients was relatively small. In conclusion, severe pneumonia frequently occurs among patients with LP and the mortality rate is high. The risk of progression to severe pneumonia is higher among patients with subnormal platelet counts and delayed antibiotic treatment >1 day. Thus, that early administration of antibiotics against Legionella spp. may be beneficial for LP patients, especially those with low platelet counts.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

ACKNOWLEDGMENTS

None.

ORCID

Jin-Young Huh https://orcid.org/0000-0003-4317-8047
Sang-Ho Choi https://orcid.org/0000-0002-4972-4531
Kyung-Wook Jo https://orcid.org/0000-0002-5949-248X
Jin Won Huh https://orcid.org/0000-0002-3449-0461
Sang-Bum Hong https://orcid.org/0000-0003-2737-7695
Tae Sun Shim https://orcid.org/0000-0001-6653-816X
Chae-Man Lim https://orcid.org/0000-0001-5400-6588
Younsuck Koh https://orcid.org/0000-0001-5066-2027

AUTHOR CONTRIBUTIONS

Conceptualization: JYH, SHC, YK. Data curation: JYH, SHC, KWJ, TSS. Formal analysis: JYH, SHC. Methodology: JYH, SHC, YK. Project administration: JWH, SBH, CML. Visualization: JYH, SHC. Writing—original draft: JYH, SHC. Writing—review & editing: JYH, SHC, YK.

REFERENCES

1. Diederen BM. Legionella spp. and Legionnaires’ disease. J Infect 2008;56:1-12.
2. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet 2016;387:376-85.
3. Carratalá J, García-Vidal C. An update on Legionella. Curr Opin Infect Dis 2010;23:152-7.
4. Morgan AJ, Glossop AI. Severe community-acquired pneumonia. BJ A Educ 2016;16:167-72.
5. Chong YP, Jung KS, Lee KH, Kim MN, Moon SM, Park S, et al. The bacterial etiology of community-acquired pneumonia in Korea: a nationwide prospective multicenter study. Infect
with Legionella pneumonia: role of the time to appropriate antibiotic therapy. Infection 2021;49:321-5.
19. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45-67.
20. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
21. Ghoneim AH, Mohammad MA, Elghamrawy MA, Embarak S. Platelet count as a predictor of outcome of hospitalized patients with community-acquired pneumonia at Zagazig University Hospitals, Egypt. J Bronchol 2020:14:11.
22. Mirsaleidi M, Peyrani P, Aliberti S, Filardo G, Bordon J, Blasi E, et al. Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest 2010;137:416-20.
23. Eriksson O, Mohlin C, Nilsson B, Ekdahl KN. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol 2019:10:1590.
24. Palm F, Sjöholm K, Malmström J, Shannon O. Complement activation occurs at the surface of platelets activated by Streptococcal M1 protein and this results in phagocytosis of platelets. J Immunol 2019;202:503-13.
25. Mintz CS, Schultz DR, Arnold PL, Johnson W. Legionella pneumophila lipopolysaccharide activates the classical complement pathway. Infect Immun 1992;60:2769-76.
26. Larsson A, Nilsson B, Eriksson M. Thrombocytopenia and platelet microvesicle formation caused by Legionella pneumophila infection. Thromb Res 1999;96:391-7.
27. Chauhan D, Shames SR. Pathogenicity and virulence of Legionella: intracellular replication and host response. Virulence 2021;12:1122-44.
28. Kao WF, Wang JT, Sheng WH, Chen YC. Community-acquired Legionnaires’ disease at a medical center in northern Taiwan. J Microbiol Immunol Infect 2019;52:465-70.
29. Zasowski EJ, Bassetti M, Blasi F, Goossens H, Rello J, Sotgiu G, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest 2020;158:929-38.